3.41 USD
0 (0%)
3.41 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 82% to AVIR. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 6.12. This target is 79.47% above the current price.
AVIR was analyzed by 9 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about AVIR.
In the previous month the buy percentage consensus was at a similar level.
AVIR was analyzed by 9 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-04-11 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2024-08-13 | Morgan Stanley | Upgrade | Underweight -> Equal-Weight |
| 2023-08-10 | JP Morgan | Downgrade | Neutral -> Underweight |
| 2023-03-16 | JP Morgan | Maintains | Neutral |
| 2023-01-27 | SVB Leerink | Maintains | Market Perform |
| 2023-01-24 | Morgan Stanley | Maintains | Underweight |
| 2022-08-15 | Morgan Stanley | Maintains | Underweight |
| 2022-03-02 | JP Morgan | Maintains | Neutral |
| 2022-03-01 | SVB Leerink | Maintains | Market Perform |
| 2022-02-16 | SVB Leerink | Maintains | Market Perform |
| 2022-01-06 | Morgan Stanley | Downgrade | Equal-Weight -> Underweight |
| 2021-11-18 | SVB Leerink | Downgrade | Outperform -> Market Perform |
| 2021-10-20 | SVB Leerink | Maintains | Outperform |
| 2021-10-20 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2021-10-05 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2021-09-09 | SVB Leerink | Initiate | Outperform |
| 2021-08-18 | Morgan Stanley | Maintains | Overweight |
| 2021-06-03 | Morgan Stanley | Maintains | Overweight |
| 2021-04-06 | Morgan Stanley | Maintains | Overweight |
ATEA PHARMACEUTICALS INC / AVIR FAQ
What is the price target for AVIR stock?
9 analysts have analysed AVIR and the average price target is 6.12 USD. This implies a price increase of 79.47% is expected in the next year compared to the current price of 3.41.
What is the consensus rating for ATEA PHARMACEUTICALS INC (AVIR) stock?
The consensus rating for ATEA PHARMACEUTICALS INC (AVIR) is 82.2222 / 100 . This indicates that analysts generally have a positive outlook on the stock.